JPH09510620A - 神経膠細胞神経栄養因子(gdnf)をコードする組み換えアデノウィルス - Google Patents
神経膠細胞神経栄養因子(gdnf)をコードする組み換えアデノウィルスInfo
- Publication number
- JPH09510620A JPH09510620A JP7524993A JP52499395A JPH09510620A JP H09510620 A JPH09510620 A JP H09510620A JP 7524993 A JP7524993 A JP 7524993A JP 52499395 A JP52499395 A JP 52499395A JP H09510620 A JPH09510620 A JP H09510620A
- Authority
- JP
- Japan
- Prior art keywords
- adenovirus
- gdnf
- cell
- dna sequence
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/235—Adenoviridae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.GDNF又はその誘導体の1つの全体又は活性部分をコードする少なくと も1つのDNA配列を含む欠失組み換えアデノウィルス。 2.DNA配列が5’位置に、及びGDNFをコードする配列を有する読み枠 に分泌配列を含むことを特徴とする請求の範囲第1項に記載のアデノウィルス。 3.DNA配列がcDNA配列であることを特徴とする請求の範囲第1又は2 項に記載のアデノウィルス。 4.DNA配列がgDNA配列であることを特徴とする請求の範囲第1又は2 項に記載のアデノウィルス。 5.DNA配列がヒトGDNFをコードすることを特徴とする請求の範囲第1 〜4項の1つに記載のアデノウィルス。 6.DNA配列が神経細胞においてそれが発現されることを可能にするシグナ ルの調節下におかれることを特徴とする請求の範囲第1〜5項の1つに記載のア デノウィルス。 7.発現シグナルがウィルスプロモーターの中から、好ましくはE1A、ML P、CMV及びRSV LTRプロモーターの中から選ばれることを特徴とする 請求の範囲第6項に記載のアデノウィルス。 8.RSV LTRプロモーターの調節下でヒトプレ−GDNFをコードする cDNA配列を含む請求の範囲第1項に記載の欠失組み換えアデノウィルス。 9.RSV LTRプロモーターの調節下でヒトプレ−GDNFをコードする gDNA配列を含む請求の範囲第1項に記載の欠失組み換えアデノウィルス。 10.神経膠細胞−由来ヒト神経栄養因子(hGDNF)又はそれらの誘導体 の全体又は活性部分をコードするDNA配列を、神経細胞においてその発現の大 部分が起こることを可能にするプロモーターの調節下に含む請求の範囲第1項に 記載の欠失組み換えアデノウィルス。 11.プロモーターが神経−特異的エノラーゼのプロモーター及びGFAPプ ロモーターの中から選ばれることを特徴とする請求の範囲第10項に記載の欠失 望組み換えアデノウィルス。 12.標的細胞におけるその複製に必要なそのゲノムの領域が欠けていること を特徴とする請求の範囲第1〜11項の1つに記載のアデノウィルス。 13.ITR、ならびに包膜を可能にし、E1遺伝子、ならびに遺伝子E2、 E4及びL1〜L5の少なくとも1つが非−機能性である配列を含むことを特徴 とする請求の範囲第12項に記載のアデノウィルス。 14.Ad2又はAd5ヒトアデノウィルス又はCAV−2イヌアデノウィル スであることを特徴とする請求の範囲第12又は13項に記載のアデノウィルス 。 15.神経変性疾患の処置及び/又は予防を目的とする製薬学的組成物の製造 のための請求の範囲第1〜14項の1つに記載のアデノウィルスの利用。 16.パーキンソン病、アルツハイマー病又はハンティングトン病、あるいは ALSの処置及び/又は予防を目的とする製薬学的組成物の製造のための請求の 範囲第15項に記載の利用。 17.請求の範囲第1〜14項の1つに記載の1種又はそれ以上の欠失組み換 えアデノウィルスを含む製薬学的組成物。 18.注入可能な形態であることを特徴とする請求の範囲第17項に記載の製 薬学的組成物。 19.104〜1014pfu/ml、好ましくは106〜1010pfu/mlの 欠失組み換えアデノウィルスを含むことを特徴とする請求の範囲第17又は18 項に記載の製薬学的組成物。 20.請求の範囲第1〜14項の1つに記載の1種又はそれ以上の欠失組み換 えアデノウィルスに感染した哺乳類細胞。 21.ヒト細胞であることを特徴とする請求の範囲第20項に記載の細胞。 22.繊維芽細胞、筋芽細胞、肝細胞、内皮細胞、神経膠細胞又は表皮細胞の 型のヒト細胞であることを特徴とする請求の範囲第20項に記載の細胞。 23.請求の範囲第20〜22項に記載の感染細胞及び細胞外マトリックスを 含む体内埋植物。 24.細胞外マトリックスが、好ましくはコラーゲン、ゼラチン、グルコサミ ノグリカン類、フィブロネクチン及びレクチン類の中から選ばれるゲル−形成化 合物を含むことを特徴とする請求の範囲第23項に記載の体内埋植物。 25.細胞外マトリックスが感染細胞の固定のための担体も含むことを特徴と する請求の範囲第23又は24項に記載の体内埋植物。 26.担体が好ましくはポリテトラフルオロエチレン繊維から成ることを特徴 とする請求の範囲第25項に記載の体内埋植物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR94/03542 | 1994-03-25 | ||
FR9403542A FR2717824B1 (fr) | 1994-03-25 | 1994-03-25 | Virus recombinants, préparation et utilisation en thérapie génique. |
PCT/FR1995/000356 WO1995026408A1 (fr) | 1994-03-25 | 1995-03-23 | Adenovirus recombinants codant pour le facteur neurotrophique des cellules gliales (gdnf) |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH09510620A true JPH09510620A (ja) | 1997-10-28 |
Family
ID=9461438
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP7524993A Pending JPH09510620A (ja) | 1994-03-25 | 1995-03-23 | 神経膠細胞神経栄養因子(gdnf)をコードする組み換えアデノウィルス |
Country Status (14)
Country | Link |
---|---|
US (1) | US6245330B1 (ja) |
EP (1) | EP0752004B1 (ja) |
JP (1) | JPH09510620A (ja) |
KR (1) | KR100403707B1 (ja) |
AT (1) | ATE335832T1 (ja) |
AU (1) | AU704910B2 (ja) |
CA (1) | CA2184841C (ja) |
DE (1) | DE69535155T2 (ja) |
FI (1) | FI963805A0 (ja) |
FR (1) | FR2717824B1 (ja) |
IL (1) | IL113109A0 (ja) |
MX (1) | MX9604024A (ja) |
WO (1) | WO1995026408A1 (ja) |
ZA (1) | ZA952433B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010279360A (ja) * | 1995-09-28 | 2010-12-16 | Amgen | 截形グリア細胞系由来神経栄養因子 |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994008026A1 (en) * | 1992-09-25 | 1994-04-14 | Rhone-Poulenc Rorer S.A. | Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain |
US20020031493A1 (en) * | 1994-03-25 | 2002-03-14 | Rhone-Poulenc Rorer S.A. | Recombinant adenoviruses coding for glial-derived cell neurotrophic factor (gdnf) |
US5733875A (en) * | 1994-11-15 | 1998-03-31 | Amgen Inc. | Methods of using GDNF as a neuroprotective agent |
US5731284A (en) * | 1995-09-28 | 1998-03-24 | Amgen Inc. | Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product |
US5929041A (en) * | 1996-02-23 | 1999-07-27 | Amgen Inc. | Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product |
US5837681A (en) * | 1996-02-23 | 1998-11-17 | Amgen Inc. | Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product |
US5741778A (en) * | 1996-03-19 | 1998-04-21 | Amgen Inc. | Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product |
FR2753379B1 (fr) * | 1996-09-13 | 1998-10-30 | Rhone Poulenc Rorer Sa | Methode de traitement de la sclerose laterale amyotrophique |
WO1998046737A2 (en) * | 1997-04-15 | 1998-10-22 | University Of Medicine And Dentistry Of New Jersey | cDNA FOR HUMAN GDNF AND PROMOTER THEREFOR WHICH ALLOWS REGULATED AND CONSTITUTIVE EXPRESSION |
US6043221A (en) | 1997-07-30 | 2000-03-28 | Amgen Inc. | Method for preventing and treating hearing loss using a neuturin protein product |
US6277820B1 (en) | 1998-04-09 | 2001-08-21 | Genentech, Inc. | Method of dopaminergic and serotonergic neuron formation from neuroprogenitor cells |
DE19816186A1 (de) * | 1998-04-14 | 1999-10-21 | Univ Muenchen L Maximilians | GDNF-kodierende DNA, Teile davon und GDNF-Varianten |
IL146694A (en) | 2001-11-22 | 2010-12-30 | Biomas Ltd | Use of an aqueous solution containing a biologically active complex of tellurium dioxide for manufacturing a medicament |
WO2003055983A2 (en) * | 2001-12-21 | 2003-07-10 | The Salk Institute For Biological Studies | Targeted retrograde gene delivery to motor neurons |
EP1694313A4 (en) * | 2003-12-18 | 2010-11-17 | Biomas Ltd | TELLURIUM DERIVATIVES FOR THE PREVENTION AND TREATMENT OF NEURODEEGENERATIVE PROCESSES |
BRPI0710800A2 (pt) | 2006-04-25 | 2012-01-17 | Univ California | administração de fatores de crescimento para o tratamento de distúrbios de snc |
JP2009535360A (ja) * | 2006-04-26 | 2009-10-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 高分子量神経治療薬の対流増加送達のための組成物および方法 |
WO2008154644A1 (en) | 2007-06-12 | 2008-12-18 | Case Western Reserve University | Targeted cell death |
MX2010012592A (es) | 2008-05-20 | 2011-05-05 | Eos Neuroscience Inc | Vectores para la administracion de proteinas sensibles a la luz y metodos de uso de las mismas. |
US20140259192A1 (en) | 2011-07-12 | 2014-09-11 | Sanofi | Transgenic animal comprising a deletion or functional deletion of the 3'utr of an endogenous gene |
WO2014152511A1 (en) | 2013-03-15 | 2014-09-25 | The Jackson Laboratory | Methods for promoting wound healing and hair growth |
WO2019174697A1 (en) | 2018-03-15 | 2019-09-19 | Coloplast A/S | Apparatus and methods for navigating ostomy appliance user to changing room |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5670488A (en) * | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
FR2688514A1 (fr) * | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
WO1994008026A1 (en) * | 1992-09-25 | 1994-04-14 | Rhone-Poulenc Rorer S.A. | Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain |
FR2702152B1 (fr) * | 1993-03-03 | 1995-05-24 | Inst Nat Sante Rech Med | Virus recombinants et leur utilisation en thérapie génique. |
-
1994
- 1994-03-25 FR FR9403542A patent/FR2717824B1/fr not_active Expired - Lifetime
-
1995
- 1995-03-23 CA CA002184841A patent/CA2184841C/fr not_active Expired - Lifetime
- 1995-03-23 US US08/716,326 patent/US6245330B1/en not_active Expired - Lifetime
- 1995-03-23 EP EP95914402A patent/EP0752004B1/fr not_active Expired - Lifetime
- 1995-03-23 WO PCT/FR1995/000356 patent/WO1995026408A1/fr active Search and Examination
- 1995-03-23 AU AU21411/95A patent/AU704910B2/en not_active Expired
- 1995-03-23 AT AT95914402T patent/ATE335832T1/de not_active IP Right Cessation
- 1995-03-23 MX MX9604024A patent/MX9604024A/es unknown
- 1995-03-23 KR KR1019960705454A patent/KR100403707B1/ko not_active IP Right Cessation
- 1995-03-23 DE DE69535155T patent/DE69535155T2/de not_active Expired - Lifetime
- 1995-03-23 JP JP7524993A patent/JPH09510620A/ja active Pending
- 1995-03-23 IL IL11310995A patent/IL113109A0/xx unknown
- 1995-03-24 ZA ZA952433A patent/ZA952433B/xx unknown
-
1996
- 1996-09-24 FI FI963805A patent/FI963805A0/fi not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010279360A (ja) * | 1995-09-28 | 2010-12-16 | Amgen | 截形グリア細胞系由来神経栄養因子 |
Also Published As
Publication number | Publication date |
---|---|
FR2717824A1 (fr) | 1995-09-29 |
ZA952433B (en) | 1996-01-15 |
EP0752004B1 (fr) | 2006-08-09 |
DE69535155T2 (de) | 2007-06-28 |
AU2141195A (en) | 1995-10-17 |
DE69535155D1 (de) | 2006-09-21 |
WO1995026408A1 (fr) | 1995-10-05 |
CA2184841A1 (fr) | 1995-10-05 |
KR100403707B1 (ko) | 2004-02-11 |
EP0752004A1 (fr) | 1997-01-08 |
FI963805A (fi) | 1996-09-24 |
FI963805A0 (fi) | 1996-09-24 |
MX9604024A (es) | 1997-09-30 |
US6245330B1 (en) | 2001-06-12 |
ATE335832T1 (de) | 2006-09-15 |
FR2717824B1 (fr) | 1996-04-26 |
CA2184841C (fr) | 2009-08-18 |
KR970702373A (ko) | 1997-05-13 |
IL113109A0 (en) | 1995-06-29 |
AU704910B2 (en) | 1999-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH09510620A (ja) | 神経膠細胞神経栄養因子(gdnf)をコードする組み換えアデノウィルス | |
KR100375856B1 (ko) | 치료물질의생체내생산을위한조성물 | |
AU712775B2 (en) | Adenoviral-vector-mediated gene transfer into medullary motor neurons | |
US6204052B1 (en) | Adenoviral vectors with reduced TNF response and partial E3 region deletion | |
JPH08510122A (ja) | 動物起源のアデノウイルスベクターおよび遺伝子治療におけるそれらの使用 | |
AU710727B2 (en) | Adenovirus comprising a gene coding for glutathion peroxidase | |
US6685934B1 (en) | Recombinant adenoviruses coding for basic fibroblast growth factors (BFGF) | |
JPH10507079A (ja) | 治療遺伝子と免疫保護遺伝子とを含む欠陥アデノウイルス | |
JP2009060919A (ja) | 神経系の細胞へのdnaのaav仲介送達 | |
KR20190104051A (ko) | 바이러스 | |
FR2712602A1 (fr) | Virus recombinants, préparation et utilisation en thérapie génique. | |
US20040224409A1 (en) | Recombinant adenoviruses coding for brain-derived neurotrophic factor (BDNF) | |
JP2002522558A (ja) | エリスロポエチンをコードするアデノウイルスベクター及び遺伝子治療におけるそれらの使用 | |
JPH09510357A (ja) | 酸性繊維芽細胞成長因子(aFGF)をコードする組み換えアデノウィルス | |
AU703793B2 (en) | Recombinant adenoviruses coding for brain-derived neurotrophic factor (BDNF) | |
US20020031493A1 (en) | Recombinant adenoviruses coding for glial-derived cell neurotrophic factor (gdnf) | |
JP2001504088A (ja) | 筋委縮性側索硬化症の治療方法 | |
US20030148952A1 (en) | Methods and materials for the recruitment of endothelial cells | |
JPH09511394A (ja) | グルタミン酸デカルボキシラーゼ(gad)活性をコードする組換えウイルス | |
JPH09510356A (ja) | 神経膠細胞成熟因子ベータ型(GMF−β)のための組み換えアデノウィルス | |
JPH09509059A (ja) | アルツハイマー病の動物モデル、調製方法および使用 | |
MXPA96004024A (es) | Virus recombinante, preparacion y utilizacion en terapia gen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20041207 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050307 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050418 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050607 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050607 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20051206 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060404 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060518 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20060608 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20070111 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20080704 |